Grace Therapeutics (NASDAQ:GRCE – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04, FiscalAI reports.
Grace Therapeutics Price Performance
Shares of NASDAQ:GRCE traded up $0.01 during trading on Friday, reaching $1.82. The stock had a trading volume of 7,680 shares, compared to its average volume of 344,258. Grace Therapeutics has a 52 week low of $1.67 and a 52 week high of $5.18. The stock has a market capitalization of $38.40 million, a PE ratio of -1.55 and a beta of 0.43. The business’s 50-day moving average price is $2.02 and its 200 day moving average price is $2.75.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on GRCE shares. Wall Street Zen lowered shares of Grace Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Zacks Research upgraded Grace Therapeutics to a “hold” rating in a report on Monday, August 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Grace Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.00.
Grace Therapeutics Company Profile
Grace Therapeutics, Inc. (NASDAQ: GRCE) is a clinical-stage biopharmaceutical company developing therapies for rare and life-threatening medical conditions. The company focuses on drug-delivery technologies intended to improve the administration, absorption, and therapeutic performance of established pharmaceutical compounds. Grace Therapeutics’ lead candidate is GTx-104, an investigational injectable formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a serious form of bleeding around the brain.
See Also
- Five stocks we like better than Grace Therapeutics
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
